Abstract Library

#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center

Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kulkarni H

Authors: Baum R, Kulkarni H, Zachert C, Kaemmerer D, Petrovitch A,

Keywords: PRRT,

#839 Complete Mesenterial Venous Obstruction – A Clinical Syndrome Unique to Neuroendocrine Neoplasms of the Small Bowel

Introduction: Neuroendocrine neoplasms of the small bowel are mostly advanced or metastasized at diagnosis. Metastases typically occur in the mesenteric root and liver.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Petrovitch A, Hommann M, Kaemmerer D, Dreßler S, Trautvetter T,

Keywords: NET,

#27 Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is save and effective. Report of thirty consecutive patients

Introduction: Patients with rapidly progressing neuroendocrine tumors presenting with high tumor load and/or severe clinical syndromes are clinically challenging and with limited life expectany. Peptide receptor radiotherapy (PRRT) and transcatheter arterial chemoembolization (TACE) have demonstrated efficacy in the treatment of neuroendocrine tumors. However, there are no reports that both therapies have been applied in combination.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Hörsch D

Authors: Hörsch D, Gräber C, Prasad V, Gotthardt T, Petrovitch A,

Keywords: PRRT, TACE,